UNSPSC 51111867: Zindoxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C21H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1IRS95M8DN, chemically known as 1h-indol-5-ol, 2-(4-(acetyloxy)phenyl)-1-ethyl-3-methyl-, acetate (ester) but generally known as zindoxifene, which bears US NIH Compound Identifier 65645. European Medicines Agency schedules Zindoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00163MIG.

UNSPSC 51111867 Zindoxifene, a Commodity code, encompasses pharmaceuticals sold through state and local cooperative purchasing vehicles, particularly generic and over-the-counter products sourced through established drug distribution networks. State and local governments procure under this code primarily through multistate cooperative purchasing alliances that consolidate demand across multiple jurisdictions and require vendors to meet strict regulatory and supply-chain compliance standards, including cGMP certification, DSCSA compliance, and relationships with authorized pharmaceutical wholesalers. Issuing bodies include state procurement offices administering multistate cooperative agreements on behalf of participating state agencies, local government facilities, and educational institutions; the Minnesota Department of Administration's Office of State Procurement, acting as administrator of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), represents the primary vehicle for recent activity.

The geographic spread of zindoxifene procurement extends across MMCAP's member jurisdictions, including Minnesota and Oregon. The Minnesota Department of Administration issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation weights 75 percent price competitiveness, 10 percent fixed pricing, and the remainder on administrative compliance, EDI capability, and contractual structure. Vendors must maintain $5 million commercial general liability coverage, $2 million network security and privacy liability, and $2 million professional liability, and agree to a 3 percent administrative fee on all purchases. No specific set-aside designations or budget values are disclosed.